Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

We plan to conduct a randomized, double-blinded, placebo-controlled clinical trial to examine
the efficacy of Aramchol at 600 mg/day orally versus identical placebo given over 12 weeks to
improve HIV-associated hepatic steatosis as measured by a validated and accurate magnetic
resonance imaging (MRI)-based technique. In this study, we propose to randomize up to 50
patients with HIV-associated NAFLD to either Aramchol or placebo for 12 weeks. We plan to
enroll a total of 55 patients, expecting some drop outs prior to randomization. After an
initial evaluation for insulin sensitivity, liver fat measurement by MRI, and total body fat
content by DEXA, patients will be randomized to receive either Aramchol 600 mg/day or placebo
orally for 12 weeks. Patients will be monitored at regular intervals for symptoms of liver
disease, side effects of medication, and serum biochemical and metabolic indices. Patients
will also be assessed for continued HIV viral load suppression and continued tolerance of
antiretroviral therapy. At the end of 12 weeks, patients will have a repeat medical
evaluation, liver fat measurement, and total body fat content measurement. Pre and post
treatment liver fat by MRI, ALT/AST, HbA1c, CRP, insulin sensitivity, and DEXA for whole body
fat will be compared. The primary end point of successful therapy will be improvement in
liver fat by MRI. Secondary end points will be improvement in total body fat, insulin
sensitivity and liver biochemistry.

Inclusion Criteria:

1. Age at entry at least 18 years.

2. And at least one of the following risk factor for more severe liver disease:
Hypertriglyceridemia based upon ATP-III guidelines, Increased LDL cholesterol or
increased total cholesterol based upon ATP-III guidelines, Decreased HDL cholesterol
based upon ATP-III guidelines, Serum alanine (ALT) or aspartate (AST) aminotransferase
activities that are above the upper limits of normal. 19 or more in women and 30 or
more in men, Overweight as defined as BMI: 25 < 30 kg/m2, Obesity as defined BMI ≥ 30
kg/m2, Hyperuricemia based upon ATP-III guidelines, Prediabetes or Diabetes by
American Diabetes Association Criteria

3. Lipodystrophy will be confirmed on both clinical and radiologic assessment and defined
as: Clinical history and/or exam by the study physician with signs of either
facial,temporal, upper or lower extremity lipo-atrophy, Documented abdominal fat
accumulation with presence of hepatic steatosis on MRI

4. An MRI-determined fat fraction classification threshold (≥5%) will be used to confirm
subjects. MR examinations will include four research sequences (three imaging
sequences and one single-voxel spectroscopy sequence) that have been developed and
refined by Dr. Sirlin, allowing for the measurement of liver fat fraction and newer
candidate MR biomarkers for future NAFLD studies. MR examinations will last 20-30
minutes and will be performed without contrast agents. Subjects will be scanned at
1.5T. To assess sequence repeatability, two sequences per subject, block randomized,
will be run three times. For MR elastography, MR imaging will be done which will
include placing a vibrating paddle over the abdomen while images are obtained. A
comprehensive screening questionnaire will be utilized prior to subjects having an
MRI. Experienced research MR technologists will perform MR examinations under the
supervision of Dr. Sirlin.

5. History of HIV documented by a previously positive HIV Elisa or PCR.

6. Stable antiretroviral (ART) regimen for at least 12 weeks prior to study inclusion.

7. Written informed consent.

Exclusion Criteria:

1. Evidence of another form of liver disease: Hepatitis B as defined as presence of
hepatitis B surface antigen (HBsAg), Hepatitis C as defined by presence of hepatitis C
virus (HCV) RNA in serum, Autoimmune hepatitis as defined by anti-nuclear antibody
(ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or
previous response to immunosuppressive therapy, Autoimmune cholestatic liver disorders
as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of
greater than 1:80 or liver histology consistent with rimary biliary cirrhosis or
elevation of alkaline phosphatase and liver histology consistent with sclerosing
cholangitis, Wilsons disease as defined by ceruloplasmin below the limits of normal
and liver histology consistent with Wilsons disease Alpha-1-antitrypsin deficiency as
defined by alpha-1-antitrypsin level less than normal and liver histology consistent
with alpha-1-antitrypsin deficiency hemochromatosis as defined by presence of 3+ or 4+
stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity
for C282Y/H63D, Drug-induced liver disease as defined on the basis of typical exposure
and history,Bile duct obstruction as shown by imaging studies.

2. Evidence of liver cirrhosis based upon clinical assessment, imaging or any of the
following lab abnormalities: INR >1.4, albumin <3.2 g/dL, platelet count <90 x
103/microliter

3. History of excess alcohol ingestion, averaging more than 30 gm/day (3 drinks per day)
in the previous 10 years, or history of alcohol intake averaging greater than 10
gm/day (1 drink per day or 7 drinks per week) in the previous one year.

4. Contraindications to MRI: The subject has any contraindication to MR imaging, such as
patients with pacemakers, metallic cardiac valves, magnetic material such as surgical
clips, implanted electronic infusion pumps or other conditions that would preclude
proximity to a strong magnetic field, the subject has a history of extreme
claustrophobia, The subject cannot fit inside the MR scanner cavity, decompensated
liver disease, Child-Pugh score greater than or equal to 7 points

6. History of gastrointestinal bypass surgery or ingestion of drugs known to produce
hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate,
tetracycline or amiodarone in the previous 6 months. 7. Recent use (within the last 90
days) of medications to treat hepatic steatosis such as pioglotazone (or medications in the
same class) or vitamin E. 8. Use of Aramchol or agents in the same class. 9. Recent use
(within the last 90 days) of insulin as an outpatient for management of diabetes.

10. HbA1c > 9 or uncontrolled diabetes. 11. Significant systemic or major illnesses other
than liver disease, including congestive heart failure, coronary artery disease,
cerebrovascular disease, pulmonary disease with hypoxia, renal failure, organ
transplantation, serious psychiatric disease, malignancy that, in the opinion of the
investigator would preclude treatment with Aramchol and adequate follow up.

12. Active substance abuse, such as alcohol, inhaled or injection drugs within the previous
one year. 13. Pregnancy or inability to practice adequate contraception in women of
childbearing potential.

14. Evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml
and/or liver mass on imaging study that is suggestive of liver cancer.

15. HIV specific exclusions: CD4 count of less than 200 cells/μL, Detectable viral
load,Changes to ART regimen in the preceding 12 weeks,Lack of alternative ART regimens
should the patient experience virologic breakthrough,History of opportunistic infection in
the preceding 12 months

16. Symptoms of uncontrolled gastrointestinal disorders involving motility, gastric acid or
gastric emptying malabsorption ,Disorders including but not limited to peptic ulcer
disease, gastroesophageal reflux, dyspepsia, gastroparesis, chronic diarrhea, chromic
constipation, gall bladder disease,pancreatitis, lactose intolerance and celiac
disease.Patients who have used anticholinergic or other drugs known to affect
gastrointestinal motility within 7 days prior to dosing and throughout the study will also
be excluded

17. Patients with hypersensitivity to Aramchol or to any of the excipients in the tablets
or with hypersensitivity to cholic acid or bile acid sequestrants

18. Any other condition, which, in the opinion of the investigators would impede competence
or compliance or possibility hinder completion of the study.